SCHEMBL18565661

SCHEMBL18565661

c1ccc2c(c1)oc1ccc(-c3ccc4c(c3)c3ccccc3n4-c3nc(-n4c5ccccc5c5cc(-c6ccc7oc8ccccc8c7c6)ccc54)nc(-n4c5ccccc5c5cc(-c6ccc7oc8ccccc8c7c6)ccc54)n3)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 1/20 0.41
CHEK2 O96017 1/20 0.40
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
AHR P35869 2/20 0.38
PLA2G2A P14555 3/20 0.37
PLA2G4A P47712 3/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
PLA2G10 O15496 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18566330 0.95 MAPT (0.38) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL20715260 0.94 CHEK2 (0.41) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL23318323 0.94 PLA2G2A (0.41) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL18566326 0.94 KDM4E (0.45) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL20634237 0.94 PLA2G2A (0.41) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL18566327 0.94 KDM4E (0.45) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL18566323 0.94 KDM4E (0.45) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL18565805 0.93 MAPT (0.41) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL18565617 0.93 AHR (0.41) MAPTALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL23604773 0.93 CHEK2 (0.44) MAPTALDH1A1NPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2019-05-14 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device EED, BMI1, CD99 MAPT 1057/4885ALDH1A1 2977/4885NPC1 2005/4885
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE EED, BMI1, CD99 MAPT 1057/4885ALDH1A1 2977/4885NPC1 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.